Fig. 6.

TNFRSF9 methylation and mRNA expression with regard to response to anti-PD-1 immunotherapy. TNFRSF9 mRNA expression levels in samples from a recently published anti-PD-1-treated cohort comprised of N = 49 responding patients (partial, mixed, and complete), N = 56 non-responding patients, and N = 16 patients with stable disease [28]. TNFRSF9 methylation at CpG targeted by bead 12 in melanoma samples from N = 19 responding (complete and partial responses) and N = 29 non-responding patients. P-values refer to Wilcoxon Mann–Whitney U and Kruskal–Wallis test, respectively. Mean levels are indicated by bars.